At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 92 enrolled
Drug / intervention
DU-176b (edoxaban) +1 moredrug
Likely dose
Enoxaparin sodium 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial)
In Brief
A Phase 3 clinical trial evaluating DU-176b (edoxaban) and Enoxaparin sodium 20mg for Venous Thromboembolism. Completed, enrolled 92 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the safety and efficacy of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective hip fracture surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
Primary CompletionAug 2009
Study CompletionFeb 2010
First PostedAug 2010
TodayJul 2026
First PostedAug 13, 2010
Enrollment StartOct 1, 2008
Primary CompletionAug 1, 2009
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.9 years ago
Interventions
DU-176b (edoxaban)drug
Enoxaparin sodium 20mgdrug